BioVie Inc. - Common stock (BIVI)
Frequently Asked Questions About BioVie Inc. - Common stock (BIVI)
Has BioVie Inc. received any partnerships or collaborations?
Yes, BioVie Inc. has entered into various partnerships and collaborations with academic institutions and industry partners aimed at advancing its research and development efforts. These collaborations help the company optimize its drug candidates and expand its research capabilities through shared expertise and resources.
How can investors stay updated on BioVie Inc.'s activities?
Investors can stay updated on BioVie Inc.'s activities by visiting the company's official website and subscribing to their press releases or investor relations newsletter. Additionally, following the company’s social media channels and participating in investor conferences can provide timely information about developments and performance.
How does BioVie Inc. contribute to the scientific community?
BioVie Inc. contributes to the scientific community through its research and development efforts, collaborating with academic institutions, and publishing findings in scientific journals. By advancing knowledge in the field of neurodegenerative diseases, the company supports greater understanding and potentially fosters further innovations in treatment.
How does BioVie Inc. ensure patient safety during clinical trials?
BioVie Inc. ensures patient safety during clinical trials by adhering to Good Clinical Practice (GCP) guidelines and regulatory requirements. The company conducts rigorous monitoring and oversight, assesses adverse events, and holds regular safety reviews to protect trial participants and maintain data integrity.
Is BioVie Inc. publicly traded?
Yes, BioVie Inc. is a publicly traded company listed on the Nasdaq under the ticker symbol BIVI. Being publicly traded allows the company to raise capital and enhance its visibility in the healthcare and investment communities.
What are BioVie Inc.'s future plans?
BioVie Inc. plans to continue its focus on advancing the clinical development of NE3107 and potentially expand its pipeline by exploring additional candidates aimed at treating neurodegenerative diseases. The company is committed to innovation and seeks to contribute significantly to the biopharmaceutical field.
What challenges does BioVie Inc. face?
BioVie Inc. faces several challenges that are typical in the biopharmaceutical sector, including navigating the complexities of clinical trials, securing funding for ongoing research, and gaining regulatory approvals. The highly competitive landscape for neurodegenerative disease treatments also poses a challenge as the company works to differentiate its products.
What clinical trials is BioVie Inc. currently conducting?
BioVie Inc. is currently conducting clinical trials for its lead product candidate, NE3107, focusing on its efficacy and safety in Alzheimer's patients. The company is engaged in Phase 2 trials to evaluate the therapeutic potential of NE3107 in improving cognition and reducing inflammation associated with the disease.
What does BioVie Inc. do?
BioVie Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, particularly those that affect the central nervous system. The company is dedicated to improving the quality of life for patients suffering from debilitating conditions, leveraging novel drug formulations and advanced delivery systems.
What financial support does BioVie Inc. have?
BioVie Inc. has received funding from private investors and public markets, having raised capital through its initial public offering (IPO) and subsequent offerings. This financial support enables the company to fund its research and clinical development activities effectively.
What is the company's lead product candidate?
BioVie Inc.'s lead product candidate is NE3107, a novel small molecule that has shown promise in preclinical studies and clinical trials for treating Alzheimer's disease. NE3107 aims to reduce inflammation and improve cognitive function, positioning it as a potential ground-breaking treatment for patients.
What is the company’s mission?
BioVie Inc.'s mission is to develop transformative therapies for patients suffering from neurodegenerative diseases by leveraging cutting-edge science and innovative approaches. The company strives to create medications that enhance the quality of life and address the underlying pathophysiology of these challenging conditions.
What is the competitive landscape for BioVie Inc.?
The competitive landscape for BioVie Inc. includes a diverse array of biotechnology and pharmaceutical companies that are also focused on developing treatments for neurodegenerative diseases. Maintaining a competitive edge requires BioVie to innovate and demonstrate the unique value propositions of its therapies compared to existing options.
What is the primary focus of BioVie Inc.'s research?
The primary focus of BioVie Inc.'s research is on developing treatments for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The company aims to create therapies that not only alleviate symptoms but also address the underlying causes of these diseases.
What is the significance of NE3107’s mechanism of action?
The significance of NE3107’s mechanism of action lies in its dual ability to reduce inflammation and improve cognitive function, which may address multiple facets of neurodegenerative diseases. By targeting key pathways implicated in Alzheimer's and similar disorders, NE3107 has the potential to offer a more comprehensive treatment approach.
What regulatory approvals has BioVie Inc. achieved?
BioVie Inc. is actively working to achieve regulatory approvals for its clinical products. While its lead candidate, NE3107, is still undergoing clinical trials, the company is focused on adhering to the guidelines set forth by the FDA and other regulatory bodies to ensure the safety and efficacy of its therapies.
When was BioVie Inc. founded?
BioVie Inc. was founded in 2017. The company was established with the vision of addressing significant unmet medical needs in the field of neurodegenerative diseases by developing innovative therapies that target these conditions.
Where is BioVie Inc. located?
BioVie Inc. is headquartered in Los Angeles, California. This strategic location provides the company with access to a vibrant biotech ecosystem, facilitating collaboration with research institutions and biotech firms in the area.
Who are the key executives at BioVie Inc.?
BioVie Inc. has a team of experienced executives with diverse backgrounds in biopharma and healthcare. The leadership team includes individuals with extensive experience in drug development, commercialization, and corporate strategy, working together to guide the company's mission and goals.
What is the current price of BioVie Inc. - Common stock?
The current price of BioVie Inc. - Common stock is 0.8898
When was BioVie Inc. - Common stock last traded?
The last trade of BioVie Inc. - Common stock was at 2:29 pm EDT on April 3rd, 2025
What is the market capitalization of BioVie Inc. - Common stock?
The market capitalization of BioVie Inc. - Common stock is 16.42M
How many shares of BioVie Inc. - Common stock are outstanding?
BioVie Inc. - Common stock has 18.45M shares outstanding.